Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Earlier, Vertex Secures NHS England Reimbursement For Groundbreaking CASGEVY Therapy For Transfusion-Dependent Beta Thalassemia

Author: Benzinga Newsdesk | August 08, 2024 02:00am

- Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today -
- CASGEVY is one of the first medicines funded by NHS England's Innovative Medicines Fund -

Posted In: VRTX